132923-06-9
Chemical Structure
19-epi-Scholaricine
- CAS No.: 132923-06-9
- Formula:C20H24N2O4
- Molecular Weight:356.42
IUPAC Name: (S)-4-(3-acetoxy-7-phenylheptyl)-1,2-phenylene diacetate
InChIKey: GNCUCBQZLQLSOF-XKEDNIFDSA-N
SMILES: O=C(C1=C2[C@]3(C4=CC=CC(O)=C4N2)[C@@](C[C@@]1([H])[C@@]5([H])[C@H](O)C)([H])N(C5)CC3)OC
Biological Activity: 19-epi-Scholaricine is an orally active indole alkaloid. 19-epi-Scholaricine downregulates the expression of profibrotic/apoptotic proteins (HRAS, HSP90AA1, KDR) and upregulates the expression of cell cycle-related protein (CDK2). 19-epi-Scholaricine suppresses ROS production and reduces the release of inflammatory mediators, thereby attenuating podocyte apoptosis, renal inflammation and oxidative stress by inhibiting AKT/mTOR. 19-epi-Scholaricine can be used in the research of chronic glomerulonephritis and membranous nephropathy[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
19-epi-Scholaricine | 99.14% | 19-epi-Scholaricine is an orally active indole alkaloid. 19-epi-Scholaricine downregulates the expression of profibrotic/apoptotic proteins (HRAS, HSP90AA1, KDR) and upregulates the expression of cell cycle-related protein (CDK2). 19-epi-Scholaricine suppresses ROS production and reduces the release of inflammatory mediators, thereby attenuating podocyte apoptosis, renal inflammation and oxidative stress by inhibiting AKT/mTOR. 19-epi-Scholaricine can be used in the research of chronic glomerulonephritis and membranous nephropathy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Guo R, et al. Pharmacological investigation of indole alkaloids from Alstonia scholaris against chronic glomerulonephritis. Phytomedicine. 2023;118:154958. [Content Brief]
- [2]. Tian CB, et al. Managing circadian rhythm involved in alleviating membranous nephropathy by alkaloids of Alstonia scholaris. Phytomedicine. 2025;148:157467. [Content Brief]
Keywords
